This lysosomal storage disease is treated by reducing complex sphingolipid accumulation with the glucosylceramide synthase inhibiter miglustat. O Type 1 diabetes Gaucher disease Krabbe disease Fabry disease

Biochemistry
6th Edition
ISBN:9781305577206
Author:Reginald H. Garrett, Charles M. Grisham
Publisher:Reginald H. Garrett, Charles M. Grisham
Chapter18: Glycolysis
Section: Chapter Questions
Problem 20P: Understanding the Mechanism of Hemolytic Anemia Genetic defects in glycolytic enzymes can have...
icon
Related questions
Question

Q10: What is the correct answer option, pick one of the choices 

This lysosomal storage disease is treated by reducing complex sphingolipid accumulation
with the glucosylceramide synthase inhibiter miglustat.
O Type 1 diabetes
Gaucher disease
Krabbe disease
Fabry disease
Transcribed Image Text:This lysosomal storage disease is treated by reducing complex sphingolipid accumulation with the glucosylceramide synthase inhibiter miglustat. O Type 1 diabetes Gaucher disease Krabbe disease Fabry disease
Expert Solution
steps

Step by step

Solved in 3 steps

Blurred answer
Knowledge Booster
Substance abuse
Learn more about
Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, biology and related others by exploring similar questions and additional content below.
Similar questions
Recommended textbooks for you
Biochemistry
Biochemistry
Biochemistry
ISBN:
9781305577206
Author:
Reginald H. Garrett, Charles M. Grisham
Publisher:
Cengage Learning